All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
About the Multiple Myeloma Hub
The Multiple Myeloma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in multiple myeloma. Our aim is to enhance knowledge in multiple myeloma, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.
The Multiple Myeloma Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage with treatment teams and researchers around the world.
The Multiple Myeloma Hub was founded in partnership with the European School of Haematology (ESH) in 2017 and we worked in close partnership together until 2025. To this date we continue to support each other in raising awareness of each other's educational offerings to ensure maximum reach and impact amongst the Multiple Myeloma community.
The ESH is a not-for-profit institution for the dissemination of information and lifelong learning founded in 1985 to promote and facilitate access to state-of-the-art and cutting-edge knowledge in haematology and related disciplines at the European level. ESH conferences showcase state-of-the-art science and provide insights into new developments in the fields of basic, clinical, and therapeutic research in haematology.
VISION
For every treatment team and researcher to have instant access to expert opinions and the latest evidence-based information in multiple myeloma, to aid in treatment decisions and improve the lives of patients globally.
MISSION
The Multiple Myeloma Hub is the solution for a time-stretched HCP to easily access impactful information that expedites learning and empowers their treatment decisions. Informed by patients, curated by world leaders and endorsed by expert societies, the Multiple Myeloma Hub supports HCPs worldwide.
PARTNERSHIPS
In 2025, the Brazilian Association of Hematology, Hemotherapy and Cell Therapy (ABHH) joins the Multiple Myeloma Hub as a partner to promote global knowledge exchange and innovation in hematology. Representing over 5,000 professionals, ABHH is committed to advancing science, education, and equity in patient care through ethical leadership, multidisciplinary collaboration, and support for the next generation of specialists.
The Multiple Myeloma Hub is partnering with the Hematology Society of Taiwan (HST), which works to disseminate and raise awareness of the latest scientific advances in hematology among specialists in the field. Established over 50 years ago, HST now consists of more than 500 members and 7 committees. The HST holds regular annual meetings and academic seminars to promote communication and knowledge exchange, supports collaborative hematology research between hospitals, and has established a formal training and accreditation system for hematologists in Taiwan.
BROUGHT TO YOU BY SES (SCIENTIFIC EDUCATION SUPPORT)
Independent medical education (IME), informed by patients, curated by world leaders, endorsed by expert societies. SES supports healthcare professionals and patients worldwide with up-to-date, accessible, and impactful educational content. Our hubs tackle information overload, providing a comprehensive central resource for healthcare professionals (HCPs) in specific disease areas that keep them up-to-date with the latest therapeutic news and world-leading opinions. Endorsed by expert societies, and a member of the gCMEp, our platforms ensure credibility and trust. By identifying and filling knowledge gaps in easily digestible formats, we facilitate continuous learning, leading to improved patient outcomes.
OUR HUBS
SES hubs allow time-stretched healthcare professionals to easily access curated scientific, medical, and clinical information that expedites their learning and empowers their treatment decisions. Informed by patients, curated by world leaders, and endorsed by expert societies, our hubs support healthcare professionals worldwide.
THE SCIENTIFIC EDUCATION SUPPORT TEAM
The Multiple Myeloma Hub is brought to you by Scientific Education Support (SES). SES loves nothing more than building communities and networks to facilitate education through collaboration, ensuring that patients have access to the latest support and treatment options. The SES team takes care of the everyday management, content generation, and uploads on the Multiple Myeloma Hub, assisting the Steering Committee in keeping the site as up to date as possible.
